A Feasibility Study To Determine T-cell Responses To Neoantigens Following Treatment With Ipilimumab In Men With Metastatic Castration-Resistant Prostate Carcinoma
Active, no longer recruiting
Phase of Trial: Phase 0
Latest Information Update: 11 Jan 2018
At a glance
- Drugs Ipilimumab (Primary)
- Indications Prostate cancer
- Focus Therapeutic Use
- 05 Jan 2018 Planned End Date changed from 1 Aug 2018 to 1 Aug 2019.
- 05 Jan 2018 Planned primary completion date changed from 1 Aug 2018 to 1 Aug 2019.
- 05 Jan 2018 Status changed from recruiting to active, no longer recruiting.